FOR IMMEDIATE RELEASE:
August 15, 2018

INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR
THE SECOND QUARTER 2018

The Company Reports A 43% Increase In Revenue And A
79% Reduction In Net Loss For The Six-Month Period Compared To 2017

IDAHO FALLS, IDAHO, August 15, 2018. International Isotopes Inc. (OTCQB: INIS) (the
“Company”) announces its financial results for the three and six months ended June 30, 2018.

Revenue for the three months ended June 30, 2018 was $2,392,306 as compared to $1,785,824 for the
same period in 2017, an overall increase of approximately 34%. Revenue for the six-month period
ended June 30, 2018 was $5,193,332, as compared to $3,620,032 for the same period in 2017, an increase
of approximately 43%. This increase in revenue for both periods was largely the result of revenue
increases in the Company’s cobalt products, nuclear medicine products, and radiological services
segments.

Gross profit for the three months ended June 30, 2018 increased approximately 48% compared with the
same period in 2017. Gross profit for the six-month period ended June 30, 2018 increased approximately
59% compared to the same period in 2017. Operating expense increased approximately 5% for the
three months ended June 30, 2018. The increase is primarily due to an increase in Salaries and Contract
Labor costs for the period. Operating expenses decreased approximately 8% for the six-month period
ended June 30, 2018, compared to the same period in 2017, largely due to decreases in both licensing
and legal costs.

The Company’s reported net loss for the three months ended June 30, 2018, decreased by
approximately 45% to $332,279, compared to a net loss of $602,195, for the same period in 2017. The
net loss for the six-month period ended June 30, 2018, was $297,875 as compared to $1,388,463 for the
same period in 2017, a decrease in loss of approximately 79%. The decrease in net loss for both periods
was largely the result of the overall increase in revenue. The significant increases in revenue and
decreased net loss for the period comparisons was largely driven by the performance of the Company’s
cobalt products, nuclear medicine products, and radiological services, business segments.
Revenue from the sale of cobalt products for the three months ended June 30, 2018 increased approximately 284% compared to the same period in 2017. Revenue from the sale of cobalt products for the six-month period ended June 30, 2018 increased approximately 115% compared to the same period in 2017. The Company has been working toward a resumption of cobalt sales by producing cobalt in the U.S. Department of Energy’s (DOE) Advanced Test Reactor (ATR) under a ten-year agreement with the DOE. A continuous amount of cobalt will start becoming available in early 2019, because of that production agreement. In the meantime, the Company has been able to acquire cobalt from an alternate supplier which has allowed the resumption of cobalt product manufacturing and resulted in the significant increase in revenue for the segment.

Revenue from radiological services for the three months ended June 30, 2018 increased approximately 63% compared to the same period in 2017. The Company reported an increase in revenue in this segment of approximately 178% for the six-month period ended June 30, 2018 compared to the same period in 2017. Most of the radiological services revenue is generated by the performance of contract field service activities in for the DOE and International Atomic Energy Agency (IAEA). The increase in revenue for both period comparisons is the result of the Company successfully securing several of these contracts during the period. The Company expects to see similar additional contract opportunities within this segment for the remainder of the year.

Revenue from nuclear medicine products for the three months ended June 30, 2018 increased approximately 15% compared to the same period in 2017. Revenue from nuclear medicine products for the six-month period ended June 30, 2018 increased approximately 20% compared to the same period in 2017. The increase in revenue within this segment for both period comparisons is due to the consolidation of RadQual LLC and TI Services due to the change in member ownership of RadQual in 2017. The Company anticipates continued strong sales of RadQual products through the remainder of the year.

Steve Laflin, President and CEO of the Company, said, “We are pleased with the continued strong financial performance of the Company during the second quarter and for the first six months of the year as compared to the same periods in 2017. As expected, the resumption of cobalt product manufacture has had a positive impact upon revenue this year and the contracts we have been able to obtain for field services have increased revenue in the radiological services segment. We believe we will continue to see strong revenue performance in both these segments for the balance of the year and continuing into 2019. We also look forward to further increases in revenue in 2019 through continued growth of our nuclear medicine products segment, the launch of new products and services within the radiochemical segment, and the availability of cobalt products from the ATR.”
### International Isotopes Inc.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales of Product</td>
<td>$2,392,306</td>
<td>$1,785,824</td>
<td>$5,193,332</td>
<td>$3,620,032</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>$1,028,742</td>
<td>$694,770</td>
<td>$2,387,360</td>
<td>$1,505,010</td>
</tr>
<tr>
<td>Total Operating Expenses</td>
<td>$1,228,136</td>
<td>$1,167,927</td>
<td>$2,437,149</td>
<td>$2,660,581</td>
</tr>
<tr>
<td>Operating (Loss)</td>
<td>($199,394)</td>
<td>($473,157)</td>
<td>($49,789)</td>
<td>($1,155,571)</td>
</tr>
<tr>
<td>Total Other Income (Expense)</td>
<td>($113,946)</td>
<td>($121,612)</td>
<td>($165,311)</td>
<td>($231,418)</td>
</tr>
<tr>
<td>Net (Loss)</td>
<td>($333,279)</td>
<td>($602,195)</td>
<td>($297,875)</td>
<td>($1,388,463)</td>
</tr>
<tr>
<td>Net (Loss) Per Common Share</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>basic and diluted</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Weighted Av. Shares Outstanding</td>
<td>411,232,012</td>
<td>406,726,706</td>
<td>409,327,531</td>
<td>406,187,935</td>
</tr>
</tbody>
</table>

### About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, a variety of Cobalt-60 products, and provides a wide selection of radioisotopes and radiochemical for medical applications, calibration, and clinical research. The Company also provides radiological services including source installation/removal, and decommissioning of various radiation units on a contract basis to clients.

### International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the timing of the resumption of cobalt production, future opportunities for field service contracts, and future performance of the Company’s business segments. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company’s filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2017. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

### FOR MORE INFORMATION, CONTACT:

David Drewitz  
Creative Options Communications